Key Takeaways TB-500 is NOT FDA approved No regulatory approval exists for TB-500 in any therapeutic indication Derived from Thymosin Beta-4: TB-500 is a synthetic fragment of the naturally occurring 43-amino-acid protein Thymosin Beta-4 (T4) No active FDA clinical trials: There are no current IND applications or FDA-registered trials for TB-500 itself Published preclinical research exists: Thymosin Beta-4 has peer-reviewed studies on wound healing, actin regulation, and cardiac repair WADA Prohibited List: TB-500 is classified under S2 (Peptide Hormones, Growth Factors) on the World Anti-Doping Agency banned substance list Research-grade availability: TB-500 is available for laboratory and investigational use only What Is TB-500
You may experience mild peeling 25 days after your visit, as the VI Peel sloughs away old skin
We specializes in strategic leadership, security strategy & corporate IT, and Information security consulting services
Intended Use: Oral bioavailability research studies Gastrointestinal tissue research in appropriate models, including studies on anti-inflammatory peptides such as KPV Pharmaceutical formulation development research Comparative pharmacokinetic investigations Peptide stability and absorption mechanism studies Academic and institutional research applications NOT Intended For: Human consumption or administration Therapeutic treatment or diagnosis Dietary supplementation Veterinary therapeutic applications without appropriate oversight Any medical applications Safety Protocols: Researchers should follow standard laboratory safety practices when handling BPC-157 Capsules: Use appropriate personal protective equipment (lab coat, gloves) Handle in well-ventilated areas Follow institutional biosafety guidelines Dispose of waste according to local regulations for pharmaceutical waste Consult material safety data sheet (MSDS) for additional safety information Follow institutional animal care and use committee (IACUC) protocols for animal research
Bei Patienten mit Disposition zu Thrombose besteht auf Grund der vorbergehend berschiessenden Thrombozytenproduktion das Risiko thromboembolischer Komplikationen
